RT Journal Article
SR Electronic
T1 Dominant extrafollicular B cell responses in severe COVID-19 disease correlate with robust viral-specific antibody production but poor clinical outcomes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.29.20083717
DO 10.1101/2020.04.29.20083717
A1 Woodruff, Matthew C.
A1 Ramonell, Richard P.
A1 Cashman, Kevin S.
A1 Nguyen, Doan C.
A1 Saini, Ankur Singh
A1 Haddad, Natalie
A1 Ley, Ariel M.
A1 Kyu, Shuya
A1 Howell, J. Christina
A1 Ozturk, Tugba
A1 Lee, Saeyun
A1 Chen, Weirong
A1 Estrada, Jacob
A1 Morrison-Porter, Andrea
A1 Derrico, Andrew
A1 Anam, Fabliha A.
A1 Sharma, Monika
A1 Wu, Henry
A1 Le, Sang N.
A1 Jenks, Scott A.
A1 Tipton, Christopher M.
A1 Daiss, John L.
A1 Hu, William T.
A1 Lee, F. Eun-Hyung
A1 Sanz, Ignacio
YR 2020
UL http://medrxiv.org/content/early/2020/06/22/2020.04.29.20083717.abstract
AB A wide clinical spectrum has become a hallmark of the SARS-CoV-2 (COVID-19) pandemic, although its immunologic underpinnings remain to be defined. We have performed deep characterization of B cell responses through high-dimensional flow cytometry to reveal substantial heterogeneity in both effector and immature populations. More notably, critically ill patients displayed hallmarks of extrafollicular B cell activation as previously described in autoimmune settings. Extrafollicular activation correlated strongly with large antibody secreting cell expansion and early production of high levels of SARS-CoV-2-specific antibodies. Yet, these patients fared poorly with elevated inflammatory biomarkers, multi-organ failure, and death. Combined, the findings strongly indicate a major pathogenic role for immune activation in subsets of COVID-19 patients. Our study suggests that, as in autoimmunity, targeted immunomodulatory therapy may be beneficial in specific patient subpopulations that can be identified by careful immune profiling.Competing Interest StatementDr. Hu reports personal fees from ViveBio, LLC, personal fees from AARP, Inc., personal fees from Biogen, Inc., grants from Fujirebio US, outside the submitted work; In addition, Dr. Hu has a patent CSF diagnosis of FTLD-TDP issued, and a patent CSF prognosis of SMA treatment pending. Dr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech.Funding StatementThis work was supported by National Institutes of Health grants: UL TR000424 (Emory Library IT), R01-AG054991 (W.T.H.), U19-AI110483 Emory Autoimmunity Center of Excellence (I.S.), P01-AI125180-01 (I.S., F.E.L.), R37-AI049660 (I.S.), 1R01AI121252 (F.E.L.), 1U01AI141993 (F.E.L), and T32-HL116271-07 (R.P.R.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All research was approved by the Emory University Institutional Review Board (Emory IRB numbers IRB00058507, IRB00057983, and IRB00058271) and was performed in accordance with all relevant guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRelevant human clinical data from the manuscript will be shared as required by the NIH upon formal acceptance to a peer-reviewed journal.